Microbiota and radiation-induced bowel toxicity: Lessons from inflammatory bowel disease for the radiation oncologist

The Lancet Oncology

Volumn 15, Issue 3, 2014, Pages

  Ferreira, Miguel R ^a,b,c   Muls, Ann ^b   Dearnaley, David P ^a,b   Andreyev, H Jervoise N ^b  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c INSTITUTO GULBENKIAN DE CIÊNCIA   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIARRHEAL AGENT; BACTERIUM LIPOPOLYSACCHARIDE; ENTOLIMOD; LACTULOSE; PLACEBO; PROBIOTIC AGENT;

BACTERIAL GROWTH; BOWEL TOXICITY; DIARRHEA; DYSBIOSIS; GENETIC ASSOCIATION; HOMEOSTASIS; HUMAN; INFLAMMATORY BOWEL DISEASE; INTESTINE FLORA; NONHUMAN; NOTE; PRIORITY JOURNAL; RADIATION DOSE; RADIATION ENTEROPATHY; RADIATION PROTECTION; RADIATION SICKNESS; RADIOTHERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; SYMBIOSIS;

ANIMALS; HUMANS; INFLAMMATORY BOWEL DISEASES; INTESTINES; MICROBIOTA; NEOPLASMS; RADIATION INJURIES; RADIOTHERAPY; SYMBIOSIS;

EID: 84894730953     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(13)70504-7     Document Type: Note

References (76)

1. Theis VS, Sripadam R, Ramani V, Lal S Chronic radiation enteritis. Clin Oncol (R Coll Radiol) 2010, 22:70-83.
2. Somosy Z, Horváth G, Telbisz A, Réz G, Pálfia Z Morphological aspects of ionizing radiation response of small intestine. Micron 2002, 33:167-178.
3. Denham JW, Hauer-Jensen M, Peters LJ Is it time for a new formalism to categorize normal tissue radiation injury?. Int J Radiat Oncol Biol Phys 2001, 50:1105-1106.
4. Andreyev J Gastrointestinal symptoms after pelvic radiotherapy: a new understanding to improve management of symptomatic patients. Lancet Oncol 2007, 8:1007-1017.
5. Yeoh EE, Fraser RJ, McGowan RE, et al. Evidence for efficacy without increased toxicity of hypofractionated radiotherapy for prostate carcinoma: early results of a phase III randomized trial. Int J Radiat Oncol Biol Phys 2003, 55:943-955.
6. Andreyev HJ Gastrointestinal problems after pelvic radiotherapy: the past, the present and the future. Clin Oncol (R Coll Radiol) 2007, 19:790-799.
7. Haton C, François A, Vandamme M, Wysocki J, Griffiths NM, Benderitter M Imbalance of the antioxidant network of mouse small intestinal mucosa after radiation exposure. Radiat Res 2007, 167:445-453.
8. Shanahan F The host-microbe interface within the gut. Best Pract Res Clin Gastroenterol 2002, 16:915-931.
9. Reiff C, Kelly D Inflammatory bowel disease, gut bacteria and probiotic therapy. Int J Med Microbiol 2010, 300:25-33.
10. Salonen A, Palva A, de Vos WM Microbial functionality in the human intestinal tract. Front Biosci (Landmark Ed) 2009, 14:3074-3084.
11. Eckburg PB, Bik EM, Bernstein CN, et al. Diversity of the human intestinal microbial flora. Science 2005, 308:1635-1638.
12. Hsiao WW, Metz C, Singh DP, Roth J The microbes of the intestine: an introduction to their metabolic and signaling capabilities. Endocrinol Metab Clin North Am 2008, 37:857-871.
13. Guarner F, Malagelada JR Gut flora in health and disease. Lancet 2003, 361:512-519.
14. Arumugam M, Raes J, Pelletier E, et al. Enterotypes of the human gut microbiome. Nature 2011, 473:174-180.
15. Holmes E, Li JV, Marchesi JR, Nicholson JK Gut microbiota composition and activity in relation to host metabolic phenotype and disease risk. Cell Metab 2012, 16:559-564.
16. Structure, function and diversity of the healthy human microbiome. Nature 2012, 486:207-214. Human Microbiome Project Consortium.
17. Vanderploeg R, Panaccione R, Ghosh S, Rioux K Influences of intestinal bacteria in human inflammatory bowel disease. Infect Dis Clin North Am 2010, 24:977-993.
18. Rawls JF, Mahowald MA, Ley RE, Gordon JI Reciprocal gut microbiota transplants from zebrafish and mice to germ-free recipients reveal host habitat selection. Cell 2006, 127:423-433.
19. Uribe A, Alam M, Midtvedt T, Smedfors B, Theodorsson E Endogenous prostaglandins and microflora modulate DNA synthesis and neuroendocrine peptides in the rat gastrointestinal tract. Scand J Gastroenterol 1997, 32:691-699.
20. Rawls JF, Samuel BS, Gordon JI Gnotobiotic zebrafish reveal evolutionarily conserved responses to the gut microbiota. Proc Natl Acad Sci USA 2004, 101:4596-4601.
21. Fujiya M, Musch MW, Nakagawa Y, et al. The Bacillus subtilis quorum-sensing molecule CSF contributes to intestinal homeostasis via OCTN2, a host cell membrane transporter. Cell Host Microbe 2007, 1:299-308.
22. Basic Clinical Radiobiology 2009, Hodder Arnold, London. M. Joiner, A. Van der Koegel (Eds.).
23. Hooper LV, Littman DR, Macpherson AJ Interactions between the microbiota and the immune system. Science 2012, 336:1268-1273.
24. Maynard CL, Elson CO, Hatton RD, Weaver CT Reciprocal interactions of the intestinal microbiota and immune system. Nature 2012, 489:231-241.
25. Burdelya LG, Krivokrysenko VI, Tallant TC, et al. An agonist of toll-like receptor 5 has radioprotective activity in mouse and primate models. Science 2008, 320:226-230.
26. Burdelya LG, Gleiberman AS, Toshkov I, et al. Toll-like receptor 5 agonist protects mice from dermatitis and oral mucositis caused by local radiation: implications for head-and-neck cancer radiotherapy. Int J Radiat Oncol Biol Phys 2012, 83:228-234.
27. Jones RM, Mercante JW, Neish AS Reactive oxygen production induced by the gut microbiota: pharmacotherapeutic implications. Curr Med Chem 2012, 19:1519-1529.
28. Morgan XC, Tickle TL, Sokol H, et al. Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment. Genome Biol 2012, 13:R79-R97.
29. Denton AS, Andreyev HJ, Forbes A, Maher EJ Systematic review for non-surgical interventions for the management of late radiation proctitis. Br J Cancer 2002, 87:134-143.
30. Azcárate-Peril MA, Sikes M, Bruno-Bárcena JM The intestinal microbiota, gastrointestinal environment and colorectal cancer: a putative role for probiotics in prevention of colorectal cancer?. Am J Physiol Gastrointest Liver Physiol 2011, 301:G401-G424.
31. Andreyev HJ, Wotherspoon A, Denham JW, Hauer-Jensen M Defining pelvic-radiation disease for the survivorship era. Lancet Oncol 2010, 11:310-312.
32. Sonis ST The pathobiology of mucositis. Nat Rev Cancer 2004, 4:277-284.
33. Denham JW, Hauer-Jensen M The radiotherapeutic injury-a complex 'wound'. Radiother Oncol 2002, 63:129-145.
34. Yarnold J, Brotons MC Pathogenetic mechanisms in radiation fibrosis. Radiother Oncol 2010, 97:149-161.
35. Dörr W, Hendry JH Consequential late effects in normal tissues. Radiother Oncol 2001, 61:223-231.
36. Livstone EM, Hersh T, Spiro HM, Floch MH The gastrointestinal microflora of irradiated mice. II. Effect of oral antibiotic administration on the colonic flora and survival of adult mice. Yale J Biol Med 1970, 42:448-454.
37. Riehl T, Cohn S, Tessner T, Schloemann S, Stenson WF Lipopolysaccharide is radioprotective in the mouse intestine through a prostaglandin-mediated mechanism. Gastroenterology 2000, 118:1106-1116.
38. Anant S, Murmu N, Houchen CW, et al. Apobec-1 protects intestine from radiation injury through posttranscriptional regulation of cyclooxygenase-2 expression. Gastroenterology 2004, 127:1139-1149.
39. Riehl TE, Newberry RD, Lorenz RG, Stenson WF TNFR1 mediates the radioprotective effects of lipopolysaccharide in the mouse intestine. Am J Physiol Gastrointest Liver Physiol 2004, 286:G166-G173.
40. Staley EM, Yarbrough VR, Schoeb TR, et al. Murine P-glycoprotein deficiency alters intestinal injury repair and blunts lipopolysaccharide-induced radioprotection. Radiat Res 2012, 178:207-216.
41. Crawford PA, Gordon JI Microbial regulation of intestinal radiosensitivity. Proc Natl Acad Sci USA 2005, 102:13254-13259.
42. Seal M, Naito Y, Barreto R, Lorenzetti A, Safran P, Marotta F Experimental radiotherapy-induced enteritis: a probiotic interventional study. J Dig Dis 2007, 8:143-147.
43. Demirer S, Aydintug S, Aslim B, et al. Effects of probiotics on radiation-induced intestinal injury in rats. Nutrition 2006, 22:179-186.
44. Andreyev J Gastrointestinal complications of pelvic radiotherapy: are they of any importance?. Gut 2005, 54:1051-1054.
45. Wos-Oxley M, Bleich A, Oxley AP, et al. Comparative evaluation of establishing a human gut microbial community within rodent models. Gut Microbes 2012, 3:234-249.
46. Husebye E, Skar V, Høverstad T, Iversen T, Melby K Abnormal intestinal motor patterns explain enteric colonization with gram-negative bacilli in late radiation enteropathy. Gastroenterology 1995, 109:1078-1089.
47. Wedlake L, Thomas K, McGough C, Andreyev HJ Small bowel bacterial overgrowth and lactose intolerance during radical pelvic radiotherapy: An observational study. Eur J Cancer 2008, 44:2212-2217.
48. Manichanh C, Varela E, Martinez C, et al. The gut microbiota predispose to the pathophysiology of acute postradiotherapy diarrhea. Am J Gastroenterol 2008, 103:1754-1761.
49. Valdagni R, Vavassori V, Rancati T, et al. Increasing the risk of late rectal bleeding after high-dose radiotherapy for prostate cancer: the case of previous abdominal surgery. Results from a prospective trial. Radiother Oncol 2012, 103:252-255.
50. Barnett GC, De Meerleer G, Gulliford SL, Sydes MR, Elliott RM, Dearnaley DP The impact of clinical factors on the development of late radiation toxicity: results from the Medical Research Council RT01 trial (ISRCTN47772397). Clin Oncol (R Coll Radiol) 2011, 23:613-624.
51. Gardenbroek TJ, Eshuis EJ, Ponsioen CI, Ubbink DT, D'Haens GR, Bemelman WA The effect of appendectomy on the course of ulcerative colitis: a systematic review. Colorectal Dis 2012, 14:545-553.
52. Marteau P, Pochart P, Doré J, Béra-Maillet C, Bernalier A, Corthier G Comparative study of bacterial groups within the human cecal and fecal microbiota. Appl Environ Microbiol 2001, 67:4939-4942.
53. Wedlake LJ, Shaw C, Whelan K, Andreyev HJ Systematic review: the efficacy of nutritional interventions to counteract acute gastrointestinal toxicity during therapeutic pelvic radiotherapy. Aliment Pharmacol Ther 2013, 37:1046-1056.
54. Abraham C, Cho JH Inflammatory bowel disease. N Engl J Med 2009, 361:2066-2078.
55. Speca S, Giusti I, Rieder F, Latella G Cellular and molecular mechanisms of intestinal fibrosis. World J Gastroenterol 2012, 18:3635-3661.
56. Chon BH, Loeffler JS The effect of nonmalignant systemic disease on tolerance to radiation therapy. Oncologist 2002, 7:136-143.
57. Zhu Y, Zhou J, Tao G Molecular aspects of chronic radiation enteritis. Clin Invest Med 2011, 34:E119-E124.
58. Linard C, Ropenga A, Vozenin-Brotons MC, Chapel A, Mathe D Abdominal irradiation increases inflammatory cytokine expression and activates NF-kappaB in rat ileal muscularis layer. Am J Physiol Gastrointest Liver Physiol 2003, 285:G556-G565.
59. Dohi T, Borodovsky A, Wu P, et al. TWEAK/Fn14 pathway: a nonredundant role in intestinal damage in mice through a TWEAK/intestinal epithelial cell axis. Gastroenterology 2009, 136:912-923.
60. Parkes M Evidence from genetics for a role of autophagy and innate immunity in IBD pathogenesis. Dig Dis 2012, 30:330-333.
61. Barnett GC, Coles CE, Elliott RM, et al. Independent validation of genes and polymorphisms reported to be associated with radiation toxicity: a prospective analysis study. Lancet Oncol 2012, 13:65-77.
62. Craven M, Egan CE, Dowd SE, et al. Inflammation drives dysbiosis and bacterial invasion in murine models of ileal Crohn's disease. PLoS One 2012, 7:e41594.
63. Hart AL, Stagg AJ, Kamm MA Use of probiotics in the treatment of inflammatory bowel disease. J Clin Gastroenterol 2003, 36:111-119.
64. Danese S, Fiocchi C Ulcerative colitis. N Engl J Med 2011, 365:1713-1725.
65. Hecht GA Inflammatory bowel disease-live transmission. N Engl J Med 2008, 358:528-530.
66. Duboc H, Rajca S, Rainteau D, et al. Connecting dysbiosis, bile-acid dysmetabolism and gut inflammation in inflammatory bowel diseases. Gut 2013, 62:531-539.
67. Bowen R, Miller P, Shanahan MT, Packey CD, Sartor RB Radiation exposure induces dysbioses throughout the small intestinal and colonic lumen and mucosa that resemble those seen in human inflammatory bowel diseases. Inflamm Bowel Dis 2011, 17(suppl 2):S86.
68. Tedelind S, Westberg F, Kjerrulf M, Vidal A Anti-inflammatory properties of the short-chain fatty acids acetate and propionate: a study with relevance to inflammatory bowel disease. World J Gastroenterol 2007, 13:2826-2832.
69. Segain JP, de la Blétière DR, Bourreille A, et al. Butyrate inhibits inflammatory responses through NFkappaB inhibition: implications for Crohn's disease. Gut 2000, 47:397-403.
70. Plöger S, Stumpff F, Penner GB, et al. Microbial butyrate and its role for barrier function in the gastrointestinal tract. Ann NY Acad Sci 2012, 1258:52-59.
71. Hille A, Herrmann MK, Kertesz T, et al. Sodium butyrate enemas in the treatment of acute radiation-induced proctitis in patients with prostate cancer and the impact on late proctitis. A prospective evaluation. Strahlenther Onkol 2008, 184:686-692.
72. Bentzen SM, Constine LS, Deasy JO, et al. Quantitative Analyses of Normal Tissue Effects in the Clinic (QUANTEC): an introduction to the scientific issues. Int J Radiat Oncol Biol Phys 2010, 76(suppl):S3-S9.
73. Covington JA, Wedlake L, Andreyev J, et al. The detection of patients at risk of gastrointestinal toxicity during pelvic radiotherapy by electronic nose and FAIMS: a pilot study. Sensors (Basel) 2012, 12:13002-13018.
74. van Nood E, Vrieze A, Nieuwdorp M, et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med 2013, 368:407-415.
75. Hamilton MJ, Weingarden AR, Sadowsky MJ, Khoruts A Standardized frozen preparation for transplantation of fecal microbiota for recurrent Clostridium difficile infection. Am J Gastroenterol 2012, 107:761-767.
76. Anderson JL, Edney RJ, Whelan K Systematic review: faecal microbiota transplantation in the management of inflammatory bowel disease. Aliment Pharmacol Ther 2012, 36:503-516.